<DOC>
	<DOC>NCT00756145</DOC>
	<brief_summary>Low molecular weight heparin (LMWH) is injected in the dialysis circuit at the start of the session. In the present study we compare 3 different methods of injection of LMWH: parameters of dialysis efficiency and clotting are measured. The study lasts 3 sessions for each patient.</brief_summary>
	<brief_title>The Use of Low Molecular Weight Heparin in Hemodiafiltration</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>chronic kidney disease stade V treated with hemodiafiltration age &gt;18 year Hematocrit &gt; 30% treatment with vitamin K antagonists treatment with other anticoagulants or heparin besides the heparin used during dialysis active bleeding, infection or malignancy heparin associated allergy hepatic failure trombocytopenia &lt; 120.000/Âµl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>stage V</keyword>
	<keyword>treated</keyword>
	<keyword>hemodiafiltration</keyword>
</DOC>